Similar articles

• [Atherosclerosis: its cellular manifestations and the mechanisms of the development of the disease in human arteries].

  Smirnov VN, Repin VS. Smirnov VN, et al. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1985;8(2):13-31. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1985. PMID: 2998415 Review. Russian. No abstract available.
• [Atherosclerosis. Description and mechanisms. Part 2: mechanisms].

  Capron L. Capron L. Rev Neurol (Paris). 1983;139(4):239-50. Rev Neurol (Paris). 1983. PMID: 6612139 French. No abstract available.
• The relationship between plasma and tissue lipids in human atherosclerosis.

  Smith EB. Smith EB. Adv Lipid Res. 1974;12(0):1-49. doi: 10.1016/b978-0-12-024912-1.50008-9. Adv Lipid Res. 1974. PMID: 4371518 Review. No abstract available.
• Lipoprotein modification: cellular mechanisms.

  Chait A, Heinecke JW. Chait A, et al. Curr Opin Lipidol. 1994 Oct;5(5):365-70. doi: 10.1097/00041433-199410000-00008. Curr Opin Lipidol. 1994. PMID: 7858911 Review.
• Prostaglandins and cyclic nucleotides. Modulators of arterial cholesterol metabolism.

  Hajjar DP. Hajjar DP. Biochem Pharmacol. 1985 Feb 1;34(3):295-300. doi: 10.1016/0006-2952(85)90034-6. Biochem Pharmacol. 1985. PMID: 2982384 No abstract available.